Trophic serves as a strategic partner for all aspects of communications for life science companies. We apply a deep understanding of both the science and business of drug development and the capital needed for success. Based on breadth and depth of experience, Trophic has become the go-to advisory for presenting corporate stories and scientific concepts. Current client portfolio ranges from biotech start-ups, listed biopharmas and small and large pharmaceutical companies.

TROPHIC TWITTER FEED

Follow us on Twitter to stay tuned on biotech news and the inner workings of the Trophic team

Modra Pharmaceuticals announced the start of patient treatment in the Phase IIb clinical study evaluating the efficacy & tolerability of the oral formulation of docetaxel, ModraDoc006/r, in #prostatecancer. Get the full details here: https://t.co/vVzpDr2s8M

Italfaramaco SpA is expanding its #drugdevelopment pipeline through a term sheet agreement w/ Neupharma which will grant them an exclusive option to develop & commercialize inhaled teicoplanin for the improved treatment of MRSA in #cysticfibrosis patients https://t.co/ItCkhsx4tc

In July's #BeanOfTheMonth, Our VP of stress management & nutrition would like to remind you that #teamwork is the foundation of any business. To read about why teamwork is crucial for success, check out this article by @Forbes : https://t.co/44yPXK4pg0

Load More...